2020 Conference on Retroviruses and Opportunistic Infections*

Rapid ART initiation at CrescentCare Health Clinic within 72 hrs of diagnosis and prior to obtaining laboratory results was effective and well tolerated in adults and young persons (18-24 yrs) with HIV.

Higher rates of virologic suppression at delivery and fewer adverse birth outcomes in treatment-naive women initiating DTG-based ART vs EFV/FTC/TDF during pregnancy.

Phase III data demonstrate that long-acting cabotegravir + rilpivirine injections every 2 months is noninferior to monthly injections at Week 48 in virologically suppressed patients with no prior virologic failure.

Long-term pooled analysis of Studies 1489 and 1490 demonstrated comparable efficacy and safety, including renal and bone outcomes, in older and younger patients initiating BIC/FTC/TAF vs DTG-based 3-drug regimens.

Switch to monthly injections of long-acting cabotegravir + rilpivirine after 20-week induction with oral 3-drug ART in treatment-naive patients noninferior to continued oral 3-drug ART for the maintenance of virologic suppression at Week 96 and demonstrates higher patient-reported satisfaction.

Detailed analysis of confirmed virologic withdrawals shows low risk of treatment-emergent resistance in treatment-naive patients treated with DTG/3TC for initial ART.

Changes in weight, body fat, BMD, and fasting lipid parameters were comparable among varying doses of islatravir + DOR vs DOR/3TC/TDF at Week 48 in ART-naive patients.

Increases in adipose tissue and predicted 10-year risk of diabetes significantly higher with use of DTG + FTC/TAF compared with DTG + FTC/TDF or EFV/FTC/TDF in treatment-naive patients initiating ART in South Africa.

Post hoc analysis found that patients initiating EFV-based ART who were categorized by CYP2B6 genotyping as slow metabolizers had less weight gain compared with extensive metabolizers and those initiating DTG-based ART.

Longer-term follow-up demonstrates continued noninferior efficacy and more favorable bone and renal safety profile of FTC/TAF vs FTC/TDF for HIV prevention in MSM and transgender women.